Allotex Announces Eye Bank Executive Corrina Patzer Joining Board of Directors

Allotex has announced that Corrina Patzer has been appointed to the company’s Board of Directors. 

"We are excited and honored to welcome Corrina as a new independent director to the Allotex BOD,” said David Muller, CEO of Allotex, “Corrina’s understanding and experience in ophthalmic tissue banking along with her dedication to patient care will provide the company with valuable guidance as we continue to grow."

Ms. Patzer brings with her over 25 years of experience in ophthalmology, anatomical donation and transplantation. She began her eye banking career as a recovery technician at Lions VisionGift (formerly Lion’s Eye Bank of Oregon), before advancing to her current role as Chief Strategy Officer, where she oversees all core operations including Surgical and Laboratory Services, Research and Development, and Donor Services. She has previously chaired the Eye Bank Association of America (EBAA) Legislative and Regulatory Affairs Committee for multiple terms, and currently serves on the EBAA Scientific Programs committee. She is a strong advocate for donors and their families and ensuring that all people wishing to help others through the gift of donation are given that opportunity.  

“I’m honored to be a part of the Allotex board, giving me the opportunity to serve donors and recipients of the gift of sight in a new way,” said Ms. Patzer. “I look forward to helping ensure that those in need are given the opportunity to improve their vision using the unique technological innovations made possible by Allotex.” 

Allotex designs and creates allogeneic corneal tissue products for the treatment of ophthalmic disorders. The company’s lead product is a micro-implant for the treatment of presbyopia. After successfully completing its European clinic trials, the company will be commercially launching its products in the EU in 2022 and plans to begin its FDA clinical trials in 2023.